Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 13/20 | 0.58 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.56 |
| ▸ | NPY1R | P25929 | 1/20 | 0.55 |
| ▸ | NPY2R | P49146 | 1/20 | 0.55 |
| ▸ | NPY4R | P50391 | 1/20 | 0.55 |
| ▸ | CTSD | P07339 | 1/20 | 0.53 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29883948 | 0.94 | NPY4R (0.57) | BACE1BACE2NPY1RNPY2RNPY4R | |
| SCHEMBL1525876 | 0.93 | BACE1 (0.64) | BACE1BACE2NPY1RNPY2RNPY4R | |
| SCHEMBL18670433 | 0.93 | BACE1 (0.64) | BACE1BACE2NPY1RNPY2RNPY4R | |
| SCHEMBL29397496 | 0.90 | BACE1 (0.63) | BACE1BACE2NPY1RNPY2RNPY4R | |
| SCHEMBL34471860 | 0.89 | BACE1 (0.67) | BACE1BACE2NPY1RNPY2RNPY4R | |
| SCHEMBL29630763 | 0.88 | NPY4R (0.51) | BACE1BACE2NPY1RNPY2RNPY4R | |
| SCHEMBL29591841 | 0.88 | BACE1 (0.52) | BACE1BACE2CTSD | |
| SCHEMBL29878491 | 0.87 | BACE1 (0.64) | BACE1BACE2CTSD | |
| SCHEMBL29440807 | 0.87 | NPY1R (0.59) | BACE1BACE2NPY1RNPY2RNPY4R | |
| SCHEMBL29549531 | 0.87 | BACE1 (0.60) | BACE1BACE2NPY1RNPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325684-A1 | POTENT ANTI-CANCER CYCLOTIDES | UNIV SOUTHERN CALIFORNIA (US) | 2025-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325684-A1 | POTENT ANTI-CANCER CYCLOTIDES | VIP, MCL1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | BACE1 2634/4885BACE2 2996/4885NPY1R 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.